Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycyte in severe traumatic brain injury
NCT00174980Phase 2Terminated
- Sponsor
- Tenax Therapeutics
- Start
- Sep 2005
- Primary completion
- Mar 2008
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of perfluoro-tert-butylcyclohexane in traumatic brain injury (TBI) (2 arms), sponsored by Tenax Therapeutics. Primary endpoints: Brain Dialysate Concentration Data at 40 hours and Safety of Oxycyte at 48 hours. Started Sep 2005; status: terminated.
02
Drugs
perfluoro-tert-butylcyclohexane
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00174980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174980.